Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.